Form 4: NeuroPace CMO Martha Morrell Reports Stock Vesting Tax
Insider Transaction Report
NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, reported a routine disposition of 357 shares of common stock to cover tax obligations related to a restricted stock unit award vesting.
Summary
- Martha Morrell, Chief Medical Officer of NeuroPace Inc. (NPCE), reported a transaction on November 27, 2025.
- The transaction involved the disposition of 357 shares of NeuroPace common stock.
- These shares were withheld by the issuer to satisfy tax withholding obligations associated with the vesting of a restricted stock unit award.
- The price per share for the disposition was $16.5.
- Following this transaction, Martha Morrell beneficially owns 80,072 shares of NeuroPace common stock.
Sentiment
Score: 5
Explanation: The filing reports a routine, non-discretionary transaction for tax withholding purposes, which is neutral in sentiment and does not indicate any positive or negative operational or financial developments for the company.
Future Outlook
No forward-looking statements or guidance were provided in this filing.
Industry Context
This is a routine insider transaction related to compensation and tax obligations, which is common across all industries for executives receiving equity awards. It does not reflect broader industry trends or competitive positioning.
Related Party Transactions
- The transaction involves the issuer (NeuroPace Inc.) withholding shares from an officer (Martha Morrell) to satisfy tax obligations related to a compensation award, which is a standard related-party transaction in the context of executive compensation.
Stakeholder Impact
- Shareholders: Minimal impact as this is a small, routine transaction for tax purposes and does not reflect a discretionary sale or change in company fundamentals.
- Employees: No direct impact beyond the reporting person, as it relates to individual compensation.
Key Dates
| Date | Description |
|---|---|
| 11/27/2025 | Date of transaction where shares were disposed for tax withholding. |
| 12/01/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
NeuroPace, NPCE, Martha Morrell, Chief Medical Officer, Form 4, Insider Transaction, Stock Vesting, Tax Withholding, Restricted Stock Unit
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.